Incannex Healthcare Ltd ADR Asset Resilience Ratio
Incannex Healthcare Ltd ADR asset resilience ratio. Incannex Healthcare Ltd ADR (IXHL) has an Asset Resilience Ratio of 0.06% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Incannex Healthcare Ltd ADR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Incannex Healthcare Ltd ADR (2010–2017)
Asset resilience ratio of Incannex Healthcare Ltd ADR from 2010 to 2017. This chart shows how Incannex Healthcare Ltd ADR's Asset Resilience Ratio has changed over time. Read Incannex Healthcare Ltd ADR (IXHL) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Incannex Healthcare Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Incannex Healthcare Ltd ADR.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.28K | 0.06% |
| Total Liquid Assets | $5.28K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Incannex Healthcare Ltd ADR maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Incannex Healthcare Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Incannex Healthcare Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Incannex Healthcare Ltd ADR Asset Resilience Ratio by Year (2010–2017)
Incannex Healthcare Ltd ADR asset resilience ratio by year from 2010 to 2017. The table below shows the annual Asset Resilience Ratio data for Incannex Healthcare Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-06-30 | 16.59% | $166.58K | $1.00 Million | +16.26pp |
| 2015-06-30 | 0.34% | $21.32K | $6.30 Million | -5.90pp |
| 2010-06-30 | 6.24% | $1.00 Million | $16.05 Million | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more